Lamisil UNO, 1% 4 g

Interaction

At the present time, the drug interaction of Lamisil® Uno is not known.

Special Instructions

Lamisil® Uno is not recommended for chronic plantar hyperkeratosis caused by Tinea pedis (moccasin type).
Lamisil® Uno is intended for external use only. The drug should not be applied to the skin of the face, it may cause irritation of the mucous membrane of the eyes. In case of accidental contact with eyes, they should be rinsed thoroughly with running water. The drug must not be taken orally!

In case of allergic reaction to the drug the film should be removed using an organic solvent (such as denatured alcohol), and then you should wash your feet with soap and water.

If allergic reactions develop, the drug should be discontinued.

For best results, the treated area should not be washed for 24 hours after the procedure. That is why it is recommended to apply Lamisil® Uno after taking a shower or bath and wash the feet again the next day at the same time.

The amount of the drug that will be required to apply the film on both feet, performing the procedure as described above, should be used. Unused residual product should be destroyed.

Improvement in clinical symptoms is usually seen within a few days. If there is no sign of improvement after one week, the diagnosis should be verified.

There is no evidence that treatment of elderly patients requires adjustment of the dosing regimen, and different side effects occur than in younger patients.

Pediatric use

The effect of Lamisil® Uno in pediatric practice has not been studied. Therefore, it is not recommended to use the drug in children under 15 years of age.

Effect on the ability to drive vehicles and machines

Lamisil® Uno when used externally does not affect the ability to drive vehicles or work with mechanisms.

Synopsis

The solution for external use is film-forming 1% transparent or slightly opaque, viscous, colorless to light yellow in color, with an odor of ethanol.

Contraindications

Hypersensitivity to the components of the drug.

With caution: Hepatic and/or renal insufficiency, alcoholism, suppression of medullary hematopoiesis, tumors, metabolic diseases, vascular occlusive disease of the extremities, children under 15 years of age (lack of sufficient clinical experience).

Side effects

Side effects are extremely rare, mild and transient.

Systemic reactions: very rare (< 1/10 000) – allergic reactions (rash, redness, bullous dermatitis and urticaria).

Local reactions: rare (>1/1000, < 1/100) – dryness, skin irritation or burning sensation on the treated skin area.

Overdose

No cases of overdose of the drug have been reported. Overdose is unlikely because the drug is produced in an amount required for single use and intended for external use.

Symptoms: if the drug is accidentally taken orally, headache, nausea, epigastric pain and dizziness are possible.

Treatment: administration of activated charcoal, if necessary symptomatic therapy in hospital.

Pregnancy use

Clinical experience of Lamisil® Uno for external use in pregnancy is very limited, the drug should be used only in strict indications.

Terbinafine is excreted with breast milk, so the drug should not be prescribed to nursing mothers.